{"commentary":{"count":23,"free_build_floor":8,"listing_floor":3,"by_channel":{"podcast":14,"youtube":8,"x_thread":1},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT03927391\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"REDOSE","nct_id":"NCT03927391","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=redose-nct03927391. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources"},"registry":{"acronym":"REDOSE","arms":[{"description":"Normal dose of enzalutamide (160mg once daily)","label":"reference (normal) dose","type":"ACTIVE_COMPARATOR"},{"description":"Reduced dose of enzalutamide (120mg once daily)","label":"test (reduced) dose","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2024-01-08","type":"ACTUAL"},"conditions":["Prostatic Neoplasms, Castration-Resistant"],"enrollment":{"count":57,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Enzalutamide","type":"DRUG"}],"last_update":"2024-06-12","lead_sponsor":"Radboud University Medical Center","official_title":"Effect of a Reduced Dose on Cognitive Side Effects of Enzalutamide in Frail (Metastatic) Castration-resistant Prostate Cancer Patients (REDOSE)","overall_status":"COMPLETED","phases":["PHASE4"],"primary_completion_date":{"date":"2024-01-08","type":"ACTUAL"},"primary_outcomes":[{"measure":"To determine the change in the CNS side effect fatigue* in frail (m)CRPC patients treated with a reduced dose of enzalutamide (120mg OD) compared to the standard dose of enzalutamide (160mg OD) after 6 weeks of treatment.","timeFrame":"6 weeks"}],"references":[{"citation":"Boerrigter E, Overbeek JK, Benoist GE, Somford DM, Hamberg P, Tol J, Scholtes B, Willemsen AECAB, Buffart LM, Kessels RPC, Mehra N, van Oort IM, van Erp NP. A Prospective Randomised Trial to Determine the Effect of a Reduced Versus Standard Dose of Enzalutamide on Side Effects in Frail Patients with Prostate Cancer. Eur Urol Oncol. 2024 Dec;7(6):1376-1383. doi: 10.1016/j.euo.2024.02.009. Epub 2024 Mar 13.","pmid":"38485614","type":"RESULT"}],"start_date":{"date":"2019-05-30","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Effect of a Reduced Dose Enzalutamide in Frail (m)CRPC Patients on Cognitive Side Effects","url":"https://clinicaltrials.gov/study/NCT03927391"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/redose-nct03927391"}